medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Separation of blood components in patients critically ill with COVID-19

Peñuela-Briceño OA, Gómez LA

Language: Spanish
References: 24
Page: 825-830
PDF size: 206.68 Kb.


ABSTRACT

Objective: To show that therapies related to plasma exchange could be considered a strategy to attenuate circulating cytokines and other inflammatory mediators in some critically ill patients with COVID-19.
Methodology: A search for publications in the databases Scielo, PubMed, Science direct and Ovid; the search was done using descriptors such as: coronavirus infection, plasmapheresis, plasma exchange, cytokine storm, inflammation, treatment, COVID-19.
Results: We obtained 112 results, including original articles, reviews, case reports, and case series. Of these articles, we selected 24 to carry out the present review of the literature. In a minority of patients, COVID-19 can present with life-threatening features, such as acute respiratory distress syndrome, septic shock, thromboembolic disease, multi-system organ failure, and associated cytokine release syndrome.
Conclusions: The suppression of cytokine release syndrome may be a key therapeutic step in the management of critically ill COVID-19 patients and plasma exchange therapy could be used as a complementary strategy to attenuate circulating cytokines and other inflammatory mediators. However, well-designed, randomized clinical trials are needed to draw definitive conclusions.


REFERENCES

  1. Report of the WHO-China Joint Mission on CoronavirusDisease 2019 (COVID-19). 2020; 2019: 16-24.

  2. Huang C, Wang Y, Li X, Ren L, et al. Articles clinical featuresof patients infected with 2019 novel coronavirus in Wuhan,China. Lancet 2020; 6736 (20): 1-10. doi:10.1016/S0140-6736(20)30183-5.

  3. Escher R, Breakey N, Lämmle B. Severe COVID-19 infectionassociated with endothelial activation. Thromb Res 2020;190 (April): 62. doi:10.1016/j.thromres.2020.04.014.

  4. Thachil J, Tang N, Gando S, Falanga A, et al. ISTH interimguidance on recognition and management of coagulopathyin COVID-19. J Thromb Haemost 2020; 18 (5): 1023-1026.doi: 10.1111/jth.14810.

  5. Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritinas an independent risk factor for severity in COVID-19patients. J Infect 2020; 81 (4): 647-679. doi: 10.1016/j.jinf.2020.06.053.

  6. Zachariah U, Nair SC, Goel A, Balasubramanian K, et al. Targetingraised von Willebrand factor levels and macrophageactivation in severe COVID-19: Consider low volume plasmaexchange and low dose steroid. Thromb Res 2020; 192: 2.doi:10.1016/j.thromres.2020.05.001.

  7. Channappanavar R, Perlman S. Pathogenic human coronavirusinfections: causes and consequences of cytokinestorm and immunopathology. Semin Immunopathol 2017;39 (5): 529-539. doi:10.1007/s00281-017-0629-x.

  8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS,Manson JJ. COVID-19: consider cytokine storm syndromesand immunosuppression. Lancet 2020; 395 (10229): 1033-1034. doi:10.1016/S0140-6736(20)30628-0.

  9. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The roleof cytokines including interleukin-6 in COVID-19 inducedpneumonia and macrophage activation syndrome-like disease.Autoimmun Rev 2020; 19 (6): 102537. doi:10.1016/j.autrev.2020.102537.

  10. Abel JJ, Rowntree LG, Turner BB. Plasma removal withreturn of corpuscles (plasmaphaeresis). J Pharmacol ExpTher 1914; 5 (6): 625-641.

  11. Daga-Ruiz D, Fonseca-San Miguel F, González-de MolinaFJ, Úbeda-Iglesias A, Navas-Pérez A, Jannone Forés R.Plasmaféresis y otras técnicas de depuración extracorpóreaen pacientes críticos. Med Intensiva 2017; 41 (3): 174-187.doi:10.1016/j.medin.2016.10.005.

  12. Gómez-Ortiz ME, Pinto-Peñaranda LF, Muñoz-Grajales C,Márquez-Hernández JD, Velásquez-Franco CJ. Plasmaféresisy recambio terapéutico de plasma en enfermedadesautoinmunes: indicaciones, complicaciones y desenlaces.Descripción de una serie de casos. Rev Colomb Reumatol2014; 21 (3): 139-145. doi:10.1016/s0121-8123(14)70162-8.

  13. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA,et al. Guidelines on the use of therapeutic apheresis inclinical practice – evidence‐based approach from theWriting Committee of the American Society for Apheresis:The Eighth Special Issue. J Clin Apher 2019; 34: 171-354.doi: 10.1002/jca.21705.

  14. Adeli SH, Asghari A, Tabarraii R, Shajari R, et al. Therapeuticplasma exchange as a rescue therapy in patients withcoronavirus disease 2019: A case series. Polish Arch InternMed 2020; 130 (5): 455-458. doi:10.20452/pamw.15340.

  15. Zhang L, Zhai H, Ma S, Chen J, Gao Y. Efficacy of therapeuticplasma exchange in severe COVID-19 patients. Br J Haematol2020; 2019: 0-2. doi:10.1111/bjh.16890.

  16. Hashemian SM, Shafigh N, Afzal G, Jamaati H, et al. Plasmapheresisreduces cytokine and immune cell levels inCOVID-19 patients with acute respiratory distress syndrome(ARDS). Pulmonology 2020. https://doi.org/10.1016/j.pulmoe.2020.10.017.

  17. Khamis F, Al-Zakwani I, Al-Hashmi S, Al-Dowaiki S, et al.Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis 2020; 99: 214-218. doi:10.1016/j.ijid.2020.06.064.

  18. Honore PM, Mugisha A, Kugener L, Redant S, et al. Therapeuticplasma exchange as a routine therapy in septicshock and as an experimental treatment for COVID-19:We are not sure. Crit Care 2020; 24: 4-5. doi:10.1186/s13054-020-02943-1.

  19. Oh WS, Heo ST, Kim SH, Choi WJ, Han MG, Kim JY. Plasmaexchange and ribavirin for rapidly progressive severe feverwith thrombocytopenia syndrome. Int J Infect Dis 2014; 18(1): 84-86. doi:10.1016/j.ijid.2013.08.011.

  20. Patel P, Nandwani V, Vanchiere J, Conrad SA, Scott LK. Useof therapeutic plasma exchange as a rescue therapy in2009 pH1N1 influenza A-An associated respiratory failureand hemodynamic shock. Pediatr Crit Care Med 2011; 12(2): 2009-2011. doi:10.1097/PCC.0b013e3181e2a569.

  21. Hill NS, Kari R, Ioana P. Pulmonary vasculopathy in acuterespiratory distress syndrome: Something new, somethingold. Am J Respir Crit Care Med 2010; 182 (9): 1093-1094.doi:10.1164/rccm.201007-1116ED.

  22. Stahl K, Schmidt JJ, Seeliger B, Schmidt B, et al. Effect oftherapeutic plasma exchange on endothelial activationand coagulation-related parameters in septic shock. CritCare 2020; 24 (1): 1-9. doi:10.1186/s13054-020-2799-5.

  23. Szczeklik W, Wawrzycka K, Włudarczyk A, Sega A, et al.Complications in patients treated with plasmapheresis inthe intensive care unit. Anaesthesiol Intensive Ther 2013;45 (1): 7-13. doi:10.5603/AIT.2013.0002.

  24. Tabibi S, Tabibi T, Conic RRZ, Banisaeed N, Streiff MB. Therapeuticplasma exchange: A potential management strategyfor critically ill COVID-19 patients. J Intensive Care Med2020; 35 (9): 827-835. doi:10.1177/0885066620940259




2020     |     www.medigraphic.com